LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors
December 21, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy
August 03, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy Positive data supports the potential of the iN-LIfT platform to...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
July 06, 2023 07:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
July 06, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
May 04, 2023 07:00 ET
|
LIfT BioSciences
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
May 04, 2023 02:00 ET
|
LIfT BioSciences
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 08:46 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 03:00 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
December 19, 2022 07:00 ET
|
LIfT BioSciences
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
December 19, 2022 02:00 ET
|
LIfT BioSciences
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...